AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored ...

EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...

Q4 2025 Management View CEO Ryan Rhodes described 2025 as a transformative year, highlighting "39% revenue growth in our core HIFU business and record commercial performance for Focal One." Rhodes ...

LYON, France, October 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the first patients have been treated in a Phase I/II study evaluating the ...

EDAP TMS, a leading medical device company, has reported record-breaking results for its fourth quarter and full year 2025 ...

AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial ...

Edap TMS SA recently published data showing that its Focal One high intensity focused ultrasound technology is non-inferior to radical prostatectomy as a first-line treatment for localized prostate ...

Semi-Live Focal One Procedure to be Conducted on August 15 t h at 5:00 pm (KST) LYON, France, August 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today ...